Related Experiment Videos
[Biological markers in thyroid tumors]
Sílvia E Matsuo1, Luciane Martins, Suzana G Leoni
1Departamento de Histologia & Embriologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP.
Arquivos Brasileiros De Endocrinologia E Metabologia
|December 22, 2004
Summary
Thyroid tumors arise from two cell types. While genetic mutations are known, they are not yet effective diagnostic or prognostic markers for targeted thyroid cancer therapy.
Area of Science:
- Endocrinology and Oncology
- Molecular Biology
- Genomics
Context:
- Thyroid tumors originate from parafollicular (medullary carcinoma) or follicular epithelial cells (goiter, adenomas, differentiated/undifferentiated carcinomas).
- Distinct biological behaviors necessitate specific therapeutic strategies for various thyroid neoplasms.
- Advancements in molecular biology and genomics have identified thyroid cancer-specific mutations.
Purpose:
- To review the primary aspects of thyroid tumorigenesis.
- To evaluate the potential of identified genetic alterations as diagnostic and prognostic markers for thyroid follicular neoplasia.
- To assess the utility of these markers in guiding targeted therapeutic approaches for thyroid cancer.
Summary:
- Thyroid tumors originate from two distinct cell lineages, medullary carcinoma and follicular epithelial cell-derived tumors.
- Numerous genetic mutations and alterations in growth factor/receptor signaling pathways are implicated in thyroid tumorigenesis.
- Current molecular markers lack efficiency for diagnosis, prognosis, or targeted therapy in thyroid follicular neoplasia.
Impact:
- Highlights the need for improved diagnostic and prognostic markers in thyroid oncology.
- Underscores the gap between understanding molecular alterations and their clinical application in thyroid cancer treatment.
- Provides a foundation for future research into clinically relevant biomarkers for thyroid follicular neoplasms.